News

ACP: PSA screening's harms outweigh benefits


 

FROM THE ANNALS OF INTERNAL MEDICINE

If they are performed, PSA tests should be conducted no more than every 4 years. "No evidence supports annual screening for prostate cancer," the ACP guidelines note.

The potential benefit of screening is vanishingly small for men older than 69 years – and for those expected to live no more than 15 years – because prostate cancer isn’t likely to cause any problems in the time they have left, the guidelines explain. For men younger than 50 years, the downstream harms "such as erectile dysfunction and urinary incontinence carry even more weight relative to any potential benefit," according to the guidelines.

Dr. Golden, Dr. Kramer, and Dr. Shekelle said they have no relevant financial disclosures.

aotto@frontlinemedcom.com

*This story was updated 4/10/13.

Pages

Recommended Reading

PLCO criteria catch more lung cancers
MDedge Internal Medicine
Lipid metabolism genes linked to breast cancer subtype
MDedge Internal Medicine
Breast cancer: Cardiac risk increases with radiation dose to heart
MDedge Internal Medicine
Contralateral prophylactic mastectomy adds complications
MDedge Internal Medicine
Gene alteration lowers bladder cancer risk
MDedge Internal Medicine
New palliative care guidelines stress certification, diversity
MDedge Internal Medicine
New blood test could identify early pancreatic cancer
MDedge Internal Medicine
Designer T cells take aim at liver metastases
MDedge Internal Medicine
High CRP augurs worse outcomes from palliative surgery for cancer
MDedge Internal Medicine
Inconclusive results seen for intermittent androgen deprivation
MDedge Internal Medicine